Avectas
Maynooth
About Avectas
Avectas is a cell engineering technology company, enabling drug developers to manufacture potent engineered cell therapies at therapeutic volumes, with high efficiency and with minimal cell disruption. Avectas technology delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of cell types including T cells for immuno-oncology applications. Unlike the current industry standard of vector-free delivery methods, cells engineered with Avectas technology require no recovery time, leading to a shorter, simpler, more cost effective process.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $38.9M
- Funding stage: Late Stage Venture
- Last round: Grant (Apr 2021)
- Website: avectas.com
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/avectas-180330 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.